Simple Urine Test Helps Patients with COPD
By LabMedica International staff writers Posted on 31 May 2017 |

Image: The Headstart test screens urine for biomarkers, and works like a rapid diagnostic test for people with chronic obstructive pulmonary disease (Photo courtesy of Mologic).
An innovative technology could hugely improve the quality of life for people who suffer from the serious lung condition called Chronic Obstructive Pulmonary Disease. The urine test, alerts these people that they are about to suffer a life-limiting lung attack.
Chronic Obstructive Pulmonary Disease (COPD) is a condition that makes it hard to breathe because of narrowing airways and damage to the lungs. COPD sufferers are prone to lung attacks, which can mean their symptoms worsen and lead to hospitalization and even death. In the UK, three million people are living with COPD and each year the condition causes 115,000 emergency admissions to hospital and 24,000 deaths.
Scientists at the University of Leicester in partnership with Mologic (https://mologic.co.uk) have unveiled the simple in-home Headstart test has already passed the first stage of the development process. The Headstart test is based upon the basic science used in a standard pregnancy test. It works by measuring biomarkers in the urine and transforms the test data into straightforward actions and medications. This test enables chronic obstructive pulmonary disease (COPD) patients to monitor their disease status at home for early indications of exacerbation. It will test the levels of key biomarkers in the urine, interpret them and identify imminent acute exacerbation and cause in 10 minutes.
The most important cause of COPD is smoking, but past exposures to fumes, chemicals and dusts at work can also contribute to causes of the condition. COPD symptoms often do not appear until significant lung damage has occurred, and they usually worsen over time, particularly if smoking exposure continues. Other signs and symptoms of COPD may include shortness of breath, especially during physical activities, wheezing, chest tightness and a chronic cough that may produce mucus.
Professor Paul Davis, chief scientific officer and Mologic co-founder, said, “We accepted the challenge of coming up with a new way to help COPD patients understand, monitor and control what’s going on in their vulnerable lungs. Our response to the challenge was to develop a simple, low-cost test, which worked in a similar way to a pregnancy test, only this one can predict impending lung problems. The test is simple enough for patients to use themselves at home, so this puts them at the center of their own care, empowering them to take control. There’s a valuable, clear but encoded message written in the substances, which we call biomarkers, when they are excreted into the urine through the kidneys. You just need to know what to look for and how to interpret the message into plain language.”
Chronic Obstructive Pulmonary Disease (COPD) is a condition that makes it hard to breathe because of narrowing airways and damage to the lungs. COPD sufferers are prone to lung attacks, which can mean their symptoms worsen and lead to hospitalization and even death. In the UK, three million people are living with COPD and each year the condition causes 115,000 emergency admissions to hospital and 24,000 deaths.
Scientists at the University of Leicester in partnership with Mologic (https://mologic.co.uk) have unveiled the simple in-home Headstart test has already passed the first stage of the development process. The Headstart test is based upon the basic science used in a standard pregnancy test. It works by measuring biomarkers in the urine and transforms the test data into straightforward actions and medications. This test enables chronic obstructive pulmonary disease (COPD) patients to monitor their disease status at home for early indications of exacerbation. It will test the levels of key biomarkers in the urine, interpret them and identify imminent acute exacerbation and cause in 10 minutes.
The most important cause of COPD is smoking, but past exposures to fumes, chemicals and dusts at work can also contribute to causes of the condition. COPD symptoms often do not appear until significant lung damage has occurred, and they usually worsen over time, particularly if smoking exposure continues. Other signs and symptoms of COPD may include shortness of breath, especially during physical activities, wheezing, chest tightness and a chronic cough that may produce mucus.
Professor Paul Davis, chief scientific officer and Mologic co-founder, said, “We accepted the challenge of coming up with a new way to help COPD patients understand, monitor and control what’s going on in their vulnerable lungs. Our response to the challenge was to develop a simple, low-cost test, which worked in a similar way to a pregnancy test, only this one can predict impending lung problems. The test is simple enough for patients to use themselves at home, so this puts them at the center of their own care, empowering them to take control. There’s a valuable, clear but encoded message written in the substances, which we call biomarkers, when they are excreted into the urine through the kidneys. You just need to know what to look for and how to interpret the message into plain language.”
Latest Clinical Chem. News
- AI-Powered Blood Test Accurately Detects Ovarian Cancer
- Automated Decentralized cfDNA NGS Assay Identifies Alterations in Advanced Solid Tumors
- Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
- First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
- Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
- ‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
- Low-Cost Portable Screening Test to Transform Kidney Disease Detection
- New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
Channels
Molecular Diagnostics
view channel
POC Diagnostic Platform Combines Immunoassay and Molecular Testing
An innovative diagnostic platform offers superior sensitivity across all sample types, including blood, compared to existing rapid tests, while maintaining a low-cost, user-friendly design.... Read more
Single Blood Test Could Detect Different Types of Cancer at Early Stages
Currently, reliable screening for only a few types of cancer is available, such as those affecting the breast, bowel, cervix (neck of the womb), and lung for individuals at high risk. While these screenings... Read moreHematology
view channel
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read more
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
New Blood Test Detects Up to Five Infectious Diseases at POC
Researchers have developed a prototype flow-through assay capable of detecting up to five different infections, with results that can be quickly analyzed and transmitted via a specialized smartphone app.... Read more
Molecular Stool Test Shows Potential for Diagnosing TB in Adults with HIV
Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, led to 1.25 million deaths in 2023, with 13% of those occurring in people living with HIV. The current primary diagnostic method for... Read morePathology
view channel
Groundbreaking Chest Pain Triage Algorithm to Transform Cardiac Care
Cardiovascular disease is responsible for a third of all deaths worldwide, and chest pain is the second most common reason for emergency department (ED) visits. With EDs often being some of the busiest... Read more
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read moreTechnology
view channel
Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read moreIndustry
view channel
Qiagen Acquires NGS Analysis Software Company Genoox
QIAGEN (Venlo, the Netherlands) has signed a definitive agreement to acquire Genoox (Tel Aviv, Israel), a provider of artificial intelligence (AI)-powered software that enables clinical labs to scale and... Read more
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more